Reading time: 5 min

The global bioengineering market reached $295.28 billion in 2025 and is projected to hit $1.48 trillion by 2035 at a 17.53% CAGR, according to Precedence Research. But the headline number obscures what is actually driving the surge: over $15 billion in AI drug discovery partnerships signed in 2025 alone, the first clinical validation of an AI-designed drug, and a GLP-1 market projected to reach $150 billion by 2035 — with the first oral weight-loss pill already on pharmacy shelves.

AI Drug Discovery: From Promise to Phase II

The year 2025 marked a turning point for AI-driven drug development. Total deal value for AI discovery partnerships exceeded $15 billion in announced milestone payments, though actual upfront payments ran closer to 2% of headline figures — a 50:1 ratio that reflects the industry’s cautious optimism about a technology that has yet to produce an FDA-approved drug.

The deal sizes tell the story of where capital is moving. Isomorphic Labs — spun out of Google DeepMind by Nobel laureates Demis Hassabis and John Jumper — raised a record $600 million Series A in March 2025. Xaira Therapeutics launched with $1 billion in committed funding, the largest initial commitment in ARCH Venture Partners’ history. Chai Discovery, backed by OpenAI and Thrive Capital, closed a $130 million Series B that valued the six-month-old company at $1.3 billion. Meanwhile, Novo Nordisk signed a deal with Deep Apple worth up to $812 million to discover and optimise compounds using AI-powered virtual screening combined with cryo-electron microscopy.

The first concrete clinical results arrived with Insilico Medicine’s rentosertib, an AI-designed molecule for idiopathic pulmonary fibrosis that showed favourable safety profiles and dose-dependent lung function improvement in Phase IIa trials. The company now runs 30 drug programmes with 10 compounds cleared by regulators for human testing. In parallel, Takeda reported in December 2025 that zasocitinib — an AI-designed tyrosine kinase 2 inhibitor originating from Nimbus Therapeutics — reduced the severity of plaque psoriasis in two late-stage clinical trials.

Early 2026 has accelerated the shift from single-asset bets to platform investments. Chai Discovery signed a multi-year deal with Eli Lilly to design novel biologics across multiple targets and build an exclusive AI model trained on Lilly’s proprietary data. GSK partnered with Noetik to deploy cancer outcome prediction models, while Pfizer teamed up with Boltz for small molecule discovery. Lilly separately committed roughly $1 billion to its TuneLab AI programme and is building a supercomputer with Nvidia for launch in early 2026.

The GLP-1 Arms Race Goes Oral

The bioengineering platforms behind next-generation GLP-1 agonists represent the market’s most commercially advanced segment. Over 100 weight-loss compounds are currently in development, more than 35 of which incorporate a GLP-1 molecule, according to BCG’s Biopharma Trends 2026 report. US prescriptions surged over 500% between 2019 and 2024.

The landmark event came in December 2025 when the FDA approved Novo Nordisk’s oral Wegovy (semaglutide 25 mg) — the first GLP-1 pill for weight management. It launched across the US in January 2026 at $149 per month for self-pay patients, demonstrating 16.6% mean weight loss in the OASIS 4 trial. Lilly’s competing oral candidate, orforglipron — a non-peptide small molecule that can be taken without food or water restrictions — is expected to receive an FDA decision as early as March 2026 after receiving a Commissioner’s National Priority Voucher for expedited review.

The pipeline goes well beyond oral formulations. Novo Nordisk’s CagriSema, combining a GLP-1 with an amylin analogue, produced approximately 22.7% weight loss in a 68-week Phase 3 trial — exceeding current injectable options. Lilly’s retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, represents what researchers describe as the most aggressive metabolic intervention yet attempted. Semaglutide patents begin expiring in China, Brazil, India, and Canada from 2026, while European and US exclusivity holds until around 2030.

The clinical scope has expanded dramatically beyond weight management. Harvard Medical School researchers report GLP-1 drugs now show efficacy across heart failure, chronic kidney disease, liver disease, obstructive sleep apnoea, and potentially substance use disorders — prompting calls to reclassify them as “multi-system metabolic modulators” rather than simple weight-loss drugs.

Market Segmentation

North America dominated the bioengineering market with a 42% revenue share in 2025, supported by what Precedence Research describes as advanced research infrastructure and strong investment activity. The US market alone stood at $109.32 billion in 2026 and is projected to reach $476.49 billion by 2035. Asia Pacific is forecast to grow fastest at an 18% CAGR, driven by expanding healthcare systems and China’s push into AI-integrated biologics and global co-development partnerships.

By segment, healthcare and medical devices captured approximately 45% of the market. The gene editing and AI-driven platforms segment is growing fastest at a 22% CAGR, while pharmaceutical and biotech companies account for 40% of end-user spending. The synthetic biology and nano-biotechnology sub-sector is expanding at an 18% CAGR, fuelled by applications in bio-based products and sustainable industrial solutions.

The Reality Check

Despite the capital surge, the sector carries significant caveats. No AI-discovered drug has achieved FDA approval as of early 2026. Multiple AI drug discovery firms deprioritised clinical programmes in 2025, announced 20–30% workforce reductions, and reported substantial net losses. Several well-funded companies shut down entirely. A survey of tech executives found 68% cite poor data quality and governance — not algorithmic capability — as the primary reason AI initiatives fail.

The financial structure of mega-deals also warrants scrutiny. When partnership values are announced at $5+ billion, upfront payments typically represent just 2% of the headline figure. The remainder depends on multiple drug candidates achieving clinical and commercial milestones, each carrying historically high failure rates. Traditional drug development still consumes 10–15 years and costs upward of $2.6 billion, with 90% of candidates failing in clinical trials — a baseline that AI has improved in preclinical stages but not yet demonstrably altered in later phases.